Shattuck Labs
STTK----
Shattuck Labs (STTK)
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated dise...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Shattuck Labs Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$14.3893.47%
Forecast & RatingStrong buy
10analysts
- Strong buy70.00%
- Buy30.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 21 hours ago
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
- Market Beat · 22 hours ago
Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at JPMorgan Chase & Co.
- PUBT · Jul 14 at 07:50 AM
Shattuck Labs posts corporate presentation outlining DR3 antibody program for inflammatory diseases
- Quartr · Jul 14 at 07:45 AM
STTK: Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity
- PUBT · Jul 7 at 06:00 PM
Shattuck Labs CTO Abhinav A. Shukla sells 410 common shares worth $2,874.1
- PUBT · Jul 2 at 07:15 PM
Shattuck Labs CMO Arundathy N. Pandite sells 30,000 shares for $210,300
